Amvuttra — Medica
Cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis
Preferred products
- Attruby
- Vyndaqel
- Vyndamax
Initial criteria
- Patient meets the standard Amyloidosis – Amvuttra Prior Authorization Policy criteria
- AND (Patient has tried ONE of Attruby, Vyndaqel, or Vyndamax [documentation required] OR Patient is currently receiving Amvuttra)
Approval duration
1 year